Ovarian carcinosarcomas: Clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum

Çiçin, İrfan; Saip, Pınar; Eralp, Yeşim; Selam, Meltem; Topuz, Samet; Özlük, Yasemin; Aydın, Yücel; Topuz, Erkan

doi:10.1016/j.ygyno.2007.09.003

Cited by 48 publications

(51 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Doo et al (20) reported that the degree of surgical cytoreduction is related to survival outcome and longest PFS and OS are achieved by non-visible disease after upfront surgical treatment in OCS. Similarly, we showed that complete resection was associated with improved survival on OCS patients in our previous study (15). Moreover, the absence of a relationship between the surgical procedure and OS is noteworthy.…”

Section: Discussionsupporting

confidence: 75%

See 1 more Smart Citation

Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas

et al. 2016

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 75%

“…Although heterologous carcinosarcomas were reported as a negative prognostic factor in many studies, sarcomatous subtypes were not found to be a prognostic factor in others (2,3,(12)(13)(14)(15). In this study, we also did not find sarcomatous subtypes to be a prognostic factor.…”

Section: Discussioncontrasting

confidence: 73%

Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas

et al. 2016

Self Cite

View full text Add to dashboard Cite

“…Although heterologous ovarian carcinosarcomas have been associated with poorer prognosis than have homologous carcinosarcomas, other studies have reported no difference in overall survival [2]. However, one report found that patients with homologous tumors had a longer median overall survival time, but that the difference was not statistically significant [18]. We found that histological subtype was not associated with progression-free (heterologous vs. homogenous, HR: 1.12, 95% CI: 0.43–4.78, p = 0.763) or overall survival (heterologous vs. homogenous, HR: 0.87, 95% CI: 0.40–3.65, p = 0.837).…”

Section: Discussionmentioning

confidence: 99%

Optimal Debulking Surgery Followed by Paclitaxel/Platinum Chemotherapy Is Very Effective in Treating Ovarian Carcinosarcomas: A Single Center Experience

Chun

Kim²,

Kim³

et al. 2011

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background: There have been only a few reports on the survival and management of patients with ovarian carcinosarcomas. We evaluated the clinical characteristics, outcomes and prognostic factors of ovarian carcinosarcomas. Methods: Retrospective analysis of data obtained from medical records of 40 patients treated at the Asan Medical Center, Seoul, Korea, between January 1989 and January 2008. Results: Median survival was significantly longer in patients <60 years of age than in those ≧60 (p = 0.001), patients with early-stage compared to advanced tumors (p = 0.035), those with optimally debulked tumors compared to suboptimally (p < 0.001) in the advanced stage, and patients treated with paclitaxel/platinum compared to patients treated with other chemotherapies (p < 0.001). The progression-free interval was longer in patients with early-stage (p = 0.003) and optimally debulked tumors (p = 0.001), as well as in those treated with paclitaxel/platinum (p = 0.049). Multivariate analysis showed that advanced-stage, non-optimal debulking and non-paclitaxel/platinum chemotherapy were significant independent predictors of a shorter progression-free interval, and that non-optimal debulking and non-paclitaxel/platinum chemotherapy were significant independent predictors of shorter overall survival. Conclusions: Early-stage optimal debulking and adequate chemotherapy can influence time to progression and survival, indicating that the most effective treatment for patients with ovarian carcinosarcomas consists of optimal debulking surgery followed by paclitaxel/platinum chemotherapy.

show abstract

“…Some researchers stated that carcinosarcomas responded better to cisplatin-based regimes (Gadducci and Romanini, 2001). Some other regimens, such as ovarian-type chemotherapeutic regimens combining cisplatin, etoposide, cyclophosphamide, doxorubicin and paclitaxel, sarcoma-type regimens combining doxorubicin, ifosfamide, and dacarbazine, were also reported for carcinosarcomas (Resnik et al, 1995;Cass et al, 1996;Cicin et al, 2008). For splenic carcinosarcoma, Kochar et al (2009) applied cisplatin and etoposide combination therapy to treat a 60-yearold Caucasian man, who died 7 months after diagnosis attributed to the wide metastasis.…”

Section: Discussionmentioning

confidence: 99%

“…Carcinosarcomas, containing both epithelial and connective tissue components, are rare malignant neoplasms, which commonly arise from the female genital tract (Steeper et al, 1983;Gadducci and Romanini, 2001;Cicin et al, 2008), and sometimes from extragenital sites (Isimbaldi et al, 1996;di Vizio et al, 2001). Carcinosarcomas originating in the spleen are extraordinarily rare.…”

Section: Introductionmentioning

confidence: 99%

Primary splenic carcinosarcoma with local invasion of chest wall: a rare case

Sun

Wang

Zhang

2017

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Abstract:We herein present a case of carcinosarcoma arising as a primary lesion in the spleen with the presence of local invasion of chest wall prior to widespread metastasis all over the body of a female aged 64 years. The detailed information of therapy and imaging evidences of morphology, histology, and immunohistochemistry are fully provided. To the best of our knowledge, this is the fifth reported case of a primary splenic carcinosarcoma and even the first case to be described with local invasion in the mongoloid. Carcinosarcoma that develops in the spleen with local invasion is extremely rare.

show abstract

Ovarian carcinosarcomas: Clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum

Cited by 48 publications

References 23 publications

Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas

Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas

Optimal Debulking Surgery Followed by Paclitaxel/Platinum Chemotherapy Is Very Effective in Treating Ovarian Carcinosarcomas: A Single Center Experience

Primary splenic carcinosarcoma with local invasion of chest wall: a rare case

Contact Info

Product

Resources

About